Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: The epidemiological evidence

TY - JOUR

T1 - Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: The epidemiological evidence

AU - Koenig, Wolfgang

AU - Khuseyinova, Natalie

PY - 2009/2

Y1 - 2009/2

N2 - INTRODUCTION: Among other lipid related biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and type II secretory phospholipase A(2) (sPLA(2)) represent emerging candidates for refined assessment of future cardiovascular disease (CVD) risk. Indeed, emerging evidence from more than prospective 15 studies conducted since 2000, clearly demonstrate the prognostic ability of increased Lp-PLA(2) concentrations or elevated activity for risk of future coronary heart disease (CHD) and stroke. Moreover, Lp-PLA(2) might have similar predictive power for both, incident CHD in initially healthy subjects, as well as for recurrent events in those with clinically manifest atherosclerosis.DISCUSSION: By contrast, to date, there are only few prospective studies that have investigated the relationship of sPLA(2) with future CVD risk. However, most of them show a positive association between increased mass or elevated activity and future atherosclerotic complications. Nonetheless, since inhibitors of Lp-PLA(2) and sPLA(2) have already been developed, these enzymes may be considered as novel therapeutic targets to treat residual risk in certain high risk patient groups.CONCLUSION: This review summarizes the epidemiologic evidence on the association between increased mass or elevated activity of these two phospholipases and risk of CVD.

AB - INTRODUCTION: Among other lipid related biomarkers, lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and type II secretory phospholipase A(2) (sPLA(2)) represent emerging candidates for refined assessment of future cardiovascular disease (CVD) risk. Indeed, emerging evidence from more than prospective 15 studies conducted since 2000, clearly demonstrate the prognostic ability of increased Lp-PLA(2) concentrations or elevated activity for risk of future coronary heart disease (CHD) and stroke. Moreover, Lp-PLA(2) might have similar predictive power for both, incident CHD in initially healthy subjects, as well as for recurrent events in those with clinically manifest atherosclerosis.DISCUSSION: By contrast, to date, there are only few prospective studies that have investigated the relationship of sPLA(2) with future CVD risk. However, most of them show a positive association between increased mass or elevated activity and future atherosclerotic complications. Nonetheless, since inhibitors of Lp-PLA(2) and sPLA(2) have already been developed, these enzymes may be considered as novel therapeutic targets to treat residual risk in certain high risk patient groups.CONCLUSION: This review summarizes the epidemiologic evidence on the association between increased mass or elevated activity of these two phospholipases and risk of CVD.

KW - 1-Alkyl-2-acetylglycerophosphocholine Esterase/antagonists & inhibitors

KW - Biomarkers

KW - Cardiovascular Diseases/diagnosis

KW - Clinical Trials as Topic

KW - Drug Delivery Systems

KW - Enzyme Inhibitors/pharmacology

KW - Humans

KW - Phospholipases A2, Secretory/antagonists & inhibitors

KW - Predictive Value of Tests

KW - Prognosis

KW - Risk Factors

U2 - 10.1007/s10557-008-6135-6

DO - 10.1007/s10557-008-6135-6

M3 - SCORING: Review article

C2 - 18949547

VL - 23

SP - 85

EP - 92

JO - CARDIOVASC DRUG THER

JF - CARDIOVASC DRUG THER

SN - 0920-3206

IS - 1

ER -